Project 1
INSTITUTION
METHODIST HOSPITAL RESEARCH INSTITUTE, TX
PRINCIPAL INVESTIGATOR
Chan, Keith Syson (Contact)
FUNDING
$356K
YEAR
2022
MOONBASE SCORE
Still being scored
LOADING MOONBASE SCORE
Abstract
PROJECT 1 SUMMARY Bladder cancer (BC) patients present with non-muscle (NMI) or muscle (MI) invasive disease, and 20% of NMI progress to MI during follow up with a major reduction in survival. Hence, for this proposal we define early bladder lesions as non-muscle-invasive bladder cancer (NMIBC) and seek to address the two major clinical gaps in NMIBC: 1) defining actionable mechanism of NIMBC progression; 2) risk stratification of NMIBC to patients likely to progress. Project 1 is unique to investigate a novel and understudied tumor restraining mechanism, i.e., how “immunofibroblasts” instruct the formation of ectopic immune cell microarchitectures known as “tertiary lymphoid structures” to mount a local anti-tumoral response. Progress in studying immunofibroblasts and their regulation of tertiary lymphoid structure (TLS) formation is hampered by the lack of preclinical study models recapitulating the TLS phenotype. Project 1 is significant to i) reveal TLS phenotype in a published cohort of human NMIBCs, ii) overcome a technical hurdle in the field by describing a consistent TLS phenotype within early bladder lesions from a carcinogen-induced mouse model, and iii) discover a candidate immunofibroblast population that co- organize TLSs with other lymphoid tissue inducer cells by single-cell RNA sequencing. Project 1 is innovative to dissect the understudied roles of these immunofibroblasts and their interactions with lymphoid tissue inducers and B cells to instruct TLS formation. Project Integration & Benchmark of Success: Project 1 will reveal biological insights into the tumor restraining role of immunofibroblasts/TLSs and how they oppose the tumor- promoting mechanisms proposed in Project 2. Furthermore, secreted proteins and factors from these immunofibroblasts/TLSs will provide new candidate biomarkers for evaluation in Project 3. Success of Project 1 will validate immunofibroblast-mediated TLS formation as a tumor-restraining mechanism in early bladder lesions and provide relevant targets for future precision intervention.
Are you the primary organization running this research?
The two tools below are built for the principal investigator & host institution behind this project.